11:42 AM EST - ChitogenX Inc : Today reported its financial results and highlights for the third quarter of the 2023 fiscal year ended on October 31, 2022. Highlights include the launch of its second orthopedic development program in meniscus repair following the development completion of its preclinical arthroscopic surgery program. The Company signed a partnership with the California Medical Innovations Institute to identify collaborative projects and pursue proof of concept research programs utilizing ChitogenX's proprietary regenerative medicine solutions. ChitogenX Inc
shares C.CHGX are trading unchanged at $0.24.
